Progress of ocular allergy treatment in 2017 starts with the fact that this is a mature therapeutic space, with a range of existing choices for clinicians and patients.
Progression in therapies from artificial tears to antihistamines and mast cell stabilizers to topical steroids provides a suitable choice for most patients with ocular allergies.1
Despite this diversity of treatment options, there is still an unmet therapeutic need for non-responders and patients with severe conditions, such as vernal or atopic keratoconjunctivitis.
For these patients, a need for new treatments persists.
Newer treatments will focus on chronic allergy and allergic inflammation, the latter disease target being particularly important for drug developers seeking multiple indications for their therapies.
Here are some therapy candidates that eye care professionals should be watching for in the future.